{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:13:35Z","timestamp":1772003615791,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01643-4","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:19:45Z","timestamp":1768036785000},"page":"1189-1207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guselkumab Treatment ADHEREnce in BulGaria of Patients with Psoriasis\u2014ADHERE-BG Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Grisha S.","family":"Mateev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdravka V.","family":"Demerdjieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumyana K.","family":"Yankova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klimentina D.","family":"Gospodinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9287-8903","authenticated-orcid":false,"given":"Boryana E.","family":"Ilieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razvigor B.","family":"Darlenski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"3","key":"1643_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s13555-025-01356-8","volume":"15","author":"Z Reguiai","year":"2025","unstructured":"Reguiai Z, Ghislain PD, Moulin P, Baudier E, Schepkens C, Sintes M, et\u00a0al. Pso-target: a new tool to identify the therapeutic expectations of psoriasis patients treated with biologics. Dermatol Ther Heidelb. 2025;15(3):707\u201319.","journal-title":"Dermatol Ther Heidelb"},{"issue":"3","key":"1643_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13555-025-01353-x","volume":"15","author":"EJ Goddard","year":"2025","unstructured":"Goddard EJ, Haughton JM, Lucas JE, Barlow SG, Fitzgerald TP, Litvintchouk AM, et\u00a0al. Patient disease characteristics and treatment patterns in mild-moderate psoriasis: results from real-world clinical practice in the United States (PROSPECT study). Dermatol Ther Heidelb. 2025;15(3):663\u201380.","journal-title":"Dermatol Ther Heidelb"},{"issue":"10","key":"1643_CR3","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","volume":"14","author":"M Augustin","year":"2024","unstructured":"Augustin M, Gottlieb AB, Lebwohl M, Pinter A, Warren RB, Puig L, et\u00a0al. Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis. Dermatol Ther Heidelb. 2024;14(10):2841\u201357.","journal-title":"Dermatol Ther Heidelb"},{"issue":"11","key":"1643_CR4","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s13555-024-01274-1","volume":"14","author":"C Miyazaki","year":"2024","unstructured":"Miyazaki C, Masuda J, Tsai PI, Saeki H. Factors affecting treatment persistence in Japanese patients with psoriasis prescribed biologics: a real-world study using an insurance claim database. Dermatol Ther Heidelb. 2024;14(11):2999\u20133015.","journal-title":"Dermatol Ther Heidelb"},{"issue":"6","key":"1643_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaad.2018.06.053","volume":"79","author":"ED Dommasch","year":"2018","unstructured":"Dommasch ED, Lee MP, Joyce CJ, Garry EM, Gagne JJ. Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: a retrospective, comparative cohort study. J Am Acad Dermatol. 2018;79(6):1061\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1643_CR6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","volume":"74","author":"JA Doshi","year":"2016","unstructured":"Doshi JA, Takeshita J, Pinto L, Li P, Yu X, Rao P, et\u00a0al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1643_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jid.2017.11.015","volume":"138","author":"RJ Thorneloe","year":"2018","unstructured":"Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L, British Association of Dermatologists Biologic Interventions R, et\u00a0al. Intentional and unintentional medication non-adherence in psoriasis: the role of patients\u2019 medication beliefs and habit strength. J Invest Dermatol. 2018;138(4):785\u201394.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1643_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000519176","volume":"238","author":"C Xu","year":"2022","unstructured":"Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR. Drug adherence and persistence of patients with moderate to severe psoriasis treated with biologic medications in a US commercially insured population. Dermatology. 2022;238(3):438\u201347.","journal-title":"Dermatology"},{"issue":"3","key":"1643_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et\u00a0al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1643_CR10","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1080\/09546634.2021.1959504","volume":"33","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Armstrong AW, Langley RG, Gebauer K, Thaci D, Bagel J, et\u00a0al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. J Dermatolog Treat. 2022;33(4):2317\u201324.","journal-title":"J Dermatolog Treat"},{"key":"1643_CR11","doi-asserted-by":"publisher","first-page":"adv00631","DOI":"10.2340\/actadv.v101.910","volume":"102","author":"T Malkonen","year":"2022","unstructured":"Malkonen T, Nuutinen P, Hallinen T, Soini E, Nissinen R, Wennerstom C, et\u00a0al. Guselkumab treatment outcomes and persistence in a nationwide real-world cohort of patients with plaque psoriasis. Acta Derm Venereol. 2022;102:adv00631.","journal-title":"Acta Derm Venereol"},{"key":"1643_CR12","doi-asserted-by":"publisher","first-page":"adv00712","DOI":"10.2340\/actadv.v102.206","volume":"102","author":"ME Van Muijen","year":"2022","unstructured":"Van Muijen ME, Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD, et\u00a0al. Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative psoriasis area and severity index scores in a prospective multicentre cohort. Acta Derm Venereol. 2022;102:adv00712.","journal-title":"Acta Derm Venereol"},{"key":"1643_CR13","doi-asserted-by":"publisher","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Roseno NAL, Aagaard D, Lorup EH, Nielsen ML, Nymand L, et\u00a0al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis\u2014A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"1643_CR14","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, et\u00a0al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131\u201341.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"1643_CR15","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1111\/jdv.13222","volume":"29","author":"F Rencz","year":"2015","unstructured":"Rencz F, Kemeny L, Gajdacsi JZ, Owczarek W, Arenberger P, Tiplica GS, et\u00a0al. Use of biologics for psoriasis in Central and Eastern European countries. J Eur Acad Dermatol Venereol. 2015;29(11):2222\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1643_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/1346-8138.17710","volume":"52","author":"Y Tada","year":"2025","unstructured":"Tada Y, Sugiura Y, Kamishima M, Takahashi S, Tanaka Y, Masuda J, et\u00a0al. Real-world safety and effectiveness of guselkumab in patients with psoriasis: a post-marketing surveillance study through up to week 52 in Japan. J Dermatol. 2025;52(6):967\u201382.","journal-title":"J Dermatol"},{"issue":"2","key":"1643_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s13555-022-00869-w","volume":"13","author":"J Yang","year":"2023","unstructured":"Yang J, Hu K, Li X, Hu J, Tan M, Zhang M, et\u00a0al. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 52 weeks: a retrospective, observational, multicenter study from China. Dermatol Ther (Heidelb). 2023;13(2):477\u201385.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1643_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12325-020-01522-8","volume":"38","author":"C Grellmann","year":"2021","unstructured":"Grellmann C, Dombrowsky W, Fabricius V, Suruki R, Sheahan A, Joeres L. Epidemiology and treatment of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis in Germany: a real-world evidence study. Adv Ther. 2021;38(1):366\u201385.","journal-title":"Adv Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01643-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:40:26Z","timestamp":1772001626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01643-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1643"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01643-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Boryana E. Ilieva is an employee of Johnson & Johnson Bulgaria EOOD. Razvigor B. Darlenski received a medical writing services fee from Johnson & Johnson Bulgaria EOOD. Grisha S. Mateev, Zdravka V. Demerdjieva, Rumyana K. Yankova, and Klimentina D. Gospodinova declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Bulgarian Independent Ethics Committee for Clinical Studies and the Bulgarian Drug Agency approved the study protocol. The study followed the Helsinki Declaration and all applicable local and international regulatory requirements. All patients signed an informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}